Recently, the 26th CPHI Worldwide — a premier annual event for the global pharmaceutical industry — was successfully held at Messe Frankfurt in Germany. As a top international platform covering the entire pharmaceutical value chain, this convention attracted nearly 2000 exhibitors and more than 60,000 professional visitors from over 160 countries and regions to explore innovation trends and cooperation opportunities in the global biopharmaceutical industry.

Grand Shuyang Life Sciences (Chengdu) Co., Ltd., as a leading enterprise in China's blood products industry, participated in the convention again with its core product matrix, leveraging an integrated approach of technology, quality, and service to achieve fruitful results during the three-day convention and further strengthen the foundation of its global expansion.

Core Product Matrix Highlighted, Showcasing China's Strength in Blood Products

At this convention, Grand Shuyang focused on clinical needs, showcasing its four core products: human albumin, human immunoglobulin for intravenous injection (IVIG), human coagulation factor IX, and human fibrinogen. It also conveyed its globalization vision: to make the clinical value and reliability of Chinese blood products recognized worldwide As the global biopharmaceutical supply chain becomes increasingly integrated, Shuyang is gradually transforming "Made in China" into "Trusted Worldwide" through continuous international registration strategies, clinical research collaborations, and quality system development.

Grand Shuyang representatives stated that "Going global is not the end, but the beginning of greater responsibility. We hope that through continuous innovation and compliance, more patients worldwide can benefit from Chinese blood products".

Significant Achievements in Established and Emerging Markets, New Momentum in Global Collaboration

During the three-day convention, Grand Shuyang secured fruitful cooperation outcomes.

Continuous breakthroughs in emerging marketsNew customers from Europe, the Middle East, Southeast Asia, and Latin America demonstrated strong interest in Grand Shuyang's products, providing a new strategic pillar for its global expansion.

Strengthening relationships with existing customers

Numerous long-term international customers visited specifically to highly commend Grand Shuyang's professional service capabilities and innovative product pipeline, and to explore broader cooperation opportunities in the future.

Today, Grand Shuyang’s products have entered many global markets, and its overseas business continues to grow rapidly. Looking ahead, the company will continue to prioritize patient needs, deepen global collaborations, expand its international clinical presence, and elevate Chinese blood products to higher standards.